Local women living with ovarian cancer linked to the BRCA gene mutation are set to have expanded access to treatment under the Pharmaceutical Benefits Scheme.
Ovarian cancer remains the most common cause of gynecological cancer deaths in Australia with the disease claiming the life of one woman every eight hours.
Krystal Barter from support organisation, Pink Hope, says the expanded listing for Lynparza will be welcome news for patients and their loved ones.
"Up to 20% of women living with ovarian cancer carry the bracket gene mutation and it can be inherited from either the mother or the father side of the family this predisposes them to a risk of ovarian cancer and if they carry this faulty gene mutation they could have up to a 40% lifetime risk of developing ovarian cancer." said Krystal.